uniQure N.V. Other Comprehensive Income (Loss), Net of Tax, Portion Attributable to Parent
uniQure N.V. (QURE) reported Other Comprehensive Income (Loss), Net of Tax, Portion Attributable to Parent of -$1.66 million for the 3-month period ending 2026-03-31, per its 10-Q filed 2026-05-05.
Financial Statements › Income Statement › Unrealized Gains
us-gaap:OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent · last filed 2026-05-05
- uniQure N.V. other comprehensive income (loss), net of tax, portion attributable to parent for the quarter ending 2026-03-31 was -$1.66M.
- uniQure N.V. other comprehensive income (loss), net of tax, portion attributable to parent for the quarter ending 2025-12-31 was $523.00K, a 86.58% decline year-over-year.
- uniQure N.V. other comprehensive income (loss), net of tax, portion attributable to parent for the quarter ending 2025-09-30 was $158.00K.
- uniQure N.V. other comprehensive income (loss), net of tax, portion attributable to parent for the quarter ending 2025-06-30 was -$5.10M.
- uniQure N.V. other comprehensive income (loss), net of tax, portion attributable to parent for fiscal 2025 was -$5.42M, a 820.05% decline from fiscal 2024.
- uniQure N.V. other comprehensive income (loss), net of tax, portion attributable to parent for fiscal 2024 was $753.00K, a 84.11% decline from fiscal 2023.
- uniQure N.V. other comprehensive income (loss), net of tax, portion attributable to parent for fiscal 2023 was $4.74M.
- uniQure N.V. other comprehensive income (loss), net of tax, portion attributable to parent for fiscal 2022 was -$29.43M.
| Period end | Other Comprehensive Income (Loss), Net of Tax, Portion Attributable to Parent 3 month | Other Comprehensive Income (Loss), Net of Tax, Portion Attributable to Parent 6 month | Other Comprehensive Income (Loss), Net of Tax, Portion Attributable to Parent 9 month | Other Comprehensive Income (Loss), Net of Tax, Portion Attributable to Parent 12 month |
|---|---|---|---|---|
| 2026-03-31 | -$1.66M 10-Q · filed 2026-05-05 | -$1.14M derived: sum of 2 quarters · filed 2026-05-05 | -$982.00K derived: sum of 3 quarters · filed 2026-05-05 | -$6.08M derived: sum of 4 quarters · filed 2026-05-05 |
| 2025-12-31 | $523.00K derived: 10-K 12 month − 10-Q 9 month · filed 2026-03-02 | $681.00K derived: sum of 2 quarters · filed 2026-03-02 | -$4.42M derived: sum of 3 quarters · filed 2026-03-02 | -$5.42M 10-K · filed 2026-03-02 |
| 2025-09-30 | $158.00K 10-Q · filed 2025-11-10 | -$4.94M derived: sum of 2 quarters · filed 2025-11-10 | -$5.95M 10-Q · filed 2025-11-10 | -$2.05M derived: sum of 4 quarters · filed 2026-05-05 |
| 2025-06-30 | -$5.10M 10-Q · filed 2025-07-29 | -$6.10M 10-Q · filed 2025-07-29 | -$2.21M derived: sum of 3 quarters · filed 2026-05-05 | -$2.58M derived: sum of 4 quarters · filed 2026-05-05 |
| 2025-03-31 | -$1.00M 10-Q · filed 2026-05-05 | $2.89M derived: sum of 2 quarters · filed 2026-05-05 | $2.52M derived: sum of 3 quarters · filed 2026-05-05 | $2.24M derived: sum of 4 quarters · filed 2026-05-05 |
| 2024-12-31 | $3.90M derived: 10-K 12 month − 10-Q 9 month · filed 2026-03-02 | $3.52M derived: sum of 2 quarters · filed 2026-03-02 | $3.24M derived: sum of 3 quarters · filed 2026-03-02 | $753.00K 10-K · filed 2026-03-02 |
| 2024-09-30 | -$378.00K 10-Q · filed 2025-11-10 | -$656.00K derived: sum of 2 quarters · filed 2025-11-10 | -$3.15M 10-Q · filed 2025-11-10 | $1.86M derived: sum of 4 quarters · filed 2026-03-02 |
| 2024-06-30 | -$278.00K 10-Q · filed 2025-07-29 | -$2.77M 10-Q · filed 2025-07-29 | $2.24M derived: sum of 3 quarters · filed 2026-03-02 | -$3.88M derived: sum of 4 quarters · filed 2026-03-02 |
| 2024-03-31 | -$2.49M 10-Q · filed 2025-05-09 | $2.52M derived: sum of 2 quarters · filed 2026-03-02 | -$3.60M derived: sum of 3 quarters · filed 2026-03-02 | -$3.55M derived: sum of 4 quarters · filed 2026-03-02 |
| 2023-12-31 | $5.00M derived: 10-K 12 month − 10-Q 9 month · filed 2026-03-02 | -$1.11M derived: sum of 2 quarters · filed 2026-03-02 | -$1.06M derived: sum of 3 quarters · filed 2026-03-02 | $4.74M 10-K · filed 2026-03-02 |
| 2023-09-30 | -$6.12M 10-Q · filed 2024-11-05 | -$6.06M derived: sum of 2 quarters · filed 2024-11-05 | -$267.00K 10-Q · filed 2024-11-05 | $34.44M derived: sum of 4 quarters · filed 2025-02-27 |
| 2023-06-30 | $54.00K 10-Q · filed 2024-08-01 | $5.85M 10-Q · filed 2024-08-01 | $40.56M derived: sum of 3 quarters · filed 2025-02-27 | $15.19M derived: sum of 4 quarters · filed 2025-02-27 |
| 2023-03-31 | $5.80M 10-Q · filed 2024-05-07 | $40.51M derived: sum of 2 quarters · filed 2025-02-27 | $15.14M derived: sum of 3 quarters · filed 2025-02-27 | -$13.19M derived: sum of 4 quarters · filed 2025-02-27 |
| 2022-12-31 | $34.71M derived: 10-K 12 month − 10-Q 9 month · filed 2025-02-27 | $9.34M derived: sum of 2 quarters · filed 2025-02-27 | -$18.98M derived: sum of 3 quarters · filed 2025-02-27 | -$29.43M 10-K · filed 2025-02-27 |
| 2022-09-30 | -$25.37M 10-Q · filed 2023-11-07 | -$53.69M derived: sum of 2 quarters · filed 2023-11-07 | -$64.14M 10-Q · filed 2023-11-07 | -$75.12M derived: sum of 4 quarters · filed 2024-02-28 |
| 2022-06-30 | -$28.32M 10-Q · filed 2023-08-01 | -$38.77M 10-Q · filed 2023-08-01 | -$49.75M derived: sum of 3 quarters · filed 2024-02-28 | -$63.03M derived: sum of 4 quarters · filed 2024-02-28 |
| 2022-03-31 | -$10.45M 10-Q · filed 2023-05-09 | -$21.42M derived: sum of 2 quarters · filed 2024-02-28 | -$34.71M derived: sum of 3 quarters · filed 2024-02-28 | -$41.65M derived: sum of 4 quarters · filed 2024-02-28 |
| 2021-12-31 | -$10.97M derived: 10-K 12 month − 10-Q 9 month · filed 2024-02-28 | -$24.26M derived: sum of 2 quarters · filed 2024-02-28 | -$31.20M derived: sum of 3 quarters · filed 2024-02-28 | -$38.76M 10-K · filed 2024-02-28 |
| 2021-09-30 | -$13.29M 10-Q · filed 2022-11-02 | -$20.23M derived: sum of 2 quarters · filed 2022-11-02 | -$27.79M 10-Q · filed 2022-11-02 | -$20.22M derived: sum of 4 quarters · filed 2023-02-27 |
| 2021-06-30 | -$6.94M 10-Q · filed 2022-08-08 | -$14.50M 10-Q · filed 2022-08-08 | -$6.93M derived: sum of 3 quarters · filed 2023-02-27 | $2.72M derived: sum of 4 quarters · filed 2023-02-27 |
| 2021-03-31 | -$7.56M 10-Q · filed 2022-05-02 | $14.00K derived: sum of 2 quarters · filed 2023-02-27 | $9.67M derived: sum of 3 quarters · filed 2023-02-27 | $14.31M derived: sum of 4 quarters · filed 2023-02-27 |
| 2020-12-31 | $7.57M derived: 10-K 12 month − 10-Q 9 month · filed 2023-02-27 | $17.23M derived: sum of 2 quarters · filed 2023-02-27 | $21.87M derived: sum of 3 quarters · filed 2023-02-27 | $16.60M 10-K · filed 2023-02-27 |
| 2020-09-30 | $9.65M 10-Q · filed 2021-10-25 | $14.30M derived: sum of 2 quarters · filed 2021-10-25 | $9.02M 10-Q · filed 2021-10-25 | $17.02M derived: sum of 4 quarters · filed 2022-02-25 |
| 2020-06-30 | $4.65M 10-Q · filed 2021-07-26 | -$630.00K 10-Q · filed 2021-07-26 | $7.36M derived: sum of 3 quarters · filed 2022-02-25 | $1.20M derived: sum of 4 quarters · filed 2022-02-25 |
| 2020-03-31 | -$5.28M 10-Q · filed 2021-05-10 | $2.72M derived: sum of 2 quarters · filed 2022-02-25 | -$3.45M derived: sum of 3 quarters · filed 2022-02-25 | -$2.24M derived: sum of 4 quarters · filed 2022-02-25 |
| 2019-12-31 | $7.99M derived: 10-K 12 month − 10-Q 9 month · filed 2022-02-25 | $1.83M derived: sum of 2 quarters · filed 2022-02-25 | $3.04M derived: sum of 3 quarters · filed 2022-02-25 | $570.00K 10-K · filed 2022-02-25 |
| 2019-09-30 | -$6.16M 10-Q · filed 2020-10-27 | -$4.96M derived: sum of 2 quarters · filed 2020-10-27 | -$7.42M 10-Q · filed 2020-10-27 | -$9.20M derived: sum of 4 quarters · filed 2021-03-01 |
| 2019-06-30 | $1.21M 10-Q · filed 2020-07-30 | -$1.26M 10-Q · filed 2020-07-30 | -$3.03M derived: sum of 3 quarters · filed 2021-03-01 | -$3.83M derived: sum of 4 quarters · filed 2021-03-01 |
| 2019-03-31 | -$2.47M 10-Q · filed 2020-04-29 | -$4.24M derived: sum of 2 quarters · filed 2021-03-01 | -$5.04M derived: sum of 3 quarters · filed 2021-03-01 | -$8.41M derived: sum of 4 quarters · filed 2021-03-01 |
| 2018-12-31 | -$1.77M derived: 10-K 12 month − 10-Q 9 month · filed 2021-03-01 | -$2.57M derived: sum of 2 quarters · filed 2021-03-01 | -$5.95M derived: sum of 3 quarters · filed 2021-03-01 | -$5.26M 10-K · filed 2021-03-01 |
| 2018-09-30 | -$799.00K 10-Q · filed 2019-10-28 | -$4.17M derived: sum of 2 quarters · filed 2019-10-28 | -$3.49M 10-Q · filed 2019-10-28 | -$1.48M derived: sum of 4 quarters · filed 2020-03-02 |
| 2018-06-30 | -$3.38M 10-Q · filed 2019-07-29 | -$2.69M 10-Q · filed 2019-07-29 | -$681.00K derived: sum of 3 quarters · filed 2020-03-02 | -$659.00K derived: sum of 4 quarters · filed 2020-03-02 |
| 2018-03-31 | $686.00K 10-Q · filed 2019-04-29 | $2.69M derived: sum of 2 quarters · filed 2020-03-02 | $2.72M derived: sum of 3 quarters · filed 2020-03-02 | $3.12M derived: sum of 4 quarters · filed 2020-03-02 |
| 2017-12-31 | $2.01M derived: 10-K 12 month − 10-Q 9 month · filed 2020-03-02 | $2.03M derived: sum of 2 quarters · filed 2020-03-02 | $2.44M derived: sum of 3 quarters · filed 2020-03-02 | $2.76M 10-K · filed 2020-03-02 |
| 2017-09-30 | $22.00K derived: 10-Q 9 month − 10-Q 6 month · filed 2017-11-01 | $426.00K derived: sum of 2 quarters · filed 2017-11-01 | $748.00K 10-Q · filed 2017-11-01 | |
| 2017-06-30 | $404.00K derived: 10-Q 6 month − 10-Q 3 month · filed 2017-08-08 | $726.00K 10-Q · filed 2017-08-08 | ||
| 2017-03-31 | $322.00K 10-Q · filed 2017-05-09 | |||
| 2016-12-31 | $271.00K 10-K · filed 2019-02-28 | |||
| 2015-12-31 | -$1.56M 10-K · filed 2018-03-14 | |||
| 2014-12-31 | -$5.39M 10-K · filed 2017-03-15 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| SELLAS Life Sciences Group, Inc. (SLS) | United States | $2.420B | -91.87 |
| Vera Therapeutics, Inc. (VERA) | United States | $2.402B | -7.67 |
| Harmony Biosciences Holdings, Inc. (HRMY) | United States | $2.399B | 11.67 |
| Nurix Therapeutics, Inc. (NRIX) | United States | $2.457B | -5.39 |
| Mineralys Therapeutics, Inc. (MLYS) | United States | $2.353B | -6.82 |
| Viridian Therapeutics, Inc.\DE (VRDN) | United States | $2.342B | -5.38 |
| SUPERNUS PHARMACEUTICALS, INC. (SUPN) | United States | $2.517B | -24.63 |
| Immunome Inc. (IMNM) | United States | $2.538B | -9.45 |
| Disc Medicine, Inc. (IRON) | United States | $2.553B | -11.40 |
| Zai Lab Ltd (ZLAB) | $2.241B | -113.34 |